AstraZeneca to buy Alexion for $39 billion to expand in immunology

AstraZeneca to buy Alexion for $39 billion to expand in immunology

Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. The deal comes in a week that AstraZeneca...
KKR Acquires Large Portfolio of U.S. Industrial Properties

KKR Acquires Large Portfolio of U.S. Industrial Properties

KKR, a leading global investment firm, announced the acquisition of a portfolio of 9.7 million square feet of industrial real estate located in seven major markets across the U.S. from High Street Logistics Properties for an aggregate purchase price of approximately...